214 related articles for article (PubMed ID: 25128147)
1. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
2. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.
Haroche J; Cohen-Aubart F; Emile JF; Donadieu J; Amoura Z
J Am Acad Dermatol; 2015 Jul; 73(1):e29-30. PubMed ID: 26089069
[No Abstract] [Full Text] [Related]
3. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.
Héritier S; Jehanne M; Leverger G; Emile JF; Alvarez JC; Haroche J; Donadieu J
JAMA Oncol; 2015 Sep; 1(6):836-8. PubMed ID: 26180941
[No Abstract] [Full Text] [Related]
5. Access to molecular guided therapy for Langerhans cell histiocytosis patients.
Charles J; Beani JC; Tardieu M; Busser B
J Am Acad Dermatol; 2015 Jul; 73(1):e31. PubMed ID: 26089071
[No Abstract] [Full Text] [Related]
6. Saving orphans: BRAF targeting of histiocytosis.
Heaney ML
Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
8. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
10. Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib.
Konstantinou MP; Lucas P; Uthurriague C; Severino-Freire M; Spenatto N; Gaudin C; Lamant L; Tournier E; Bulai-Livideanu C; Meyer N; Paul C
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e120-e121. PubMed ID: 32757402
[No Abstract] [Full Text] [Related]
11. Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
Bentel JM; Thomas MA; Rodgers JJ; Arooj M; Gray E; Allcock R; Fermoyle S; Mancera RL; Cannell P; Parry J
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28455460
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
14. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
15. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
16. Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses.
Oishi N; Kondo T; Mochizuki K; Inoue T; Kasai K; Nakazawa T; Mitsumori T; Katoh R
Hum Pathol; 2014 Jun; 45(6):1302-5. PubMed ID: 24703101
[TBL] [Abstract][Full Text] [Related]
17. Clinical challenges in a patient with two BRAF V600E-mutated diseases.
Willenbacher E; Willenbacher W; Loeffler-Ragg J
Thorax; 2019 Jun; 74(6):620-622. PubMed ID: 30661020
[No Abstract] [Full Text] [Related]
18. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
19. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.
Dimmler A; Geddert H; Werner M; Faller G
Virchows Arch; 2017 Apr; 470(4):429-435. PubMed ID: 28220299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
